🇺🇸 LNTH — Lantheus Holdings, Inc.

Salud Mantener
← Volver

Precio actual

100,80 USD

Máx. histórico

123,62

845 días

Caída desde máximo

-18,46%

Rango 52 semanas

50,16 – 111,86

Variación hoy

+0,49%

Cierre anterior

100,31

Rango de hoy

100,26 – 100,83

Volumen hoy

748.573

Peor caída histórica

-78,62%

17/08/2015 → 08/02/2016

Recuperado en 202 días

Volatilidad anualizada ⓘ

63,44%

Información
Nombre completo
Lantheus Holdings, Inc.
Divisa
USD
Mercado
NasdaqGM
Sector
Salud
Industria
Drug Manufacturers - Specialty & Generic
Empleados
1.193
PER ⓘ
24,41 (puede no estar actualizado)
Dividend yield
0,00% (puede no estar actualizado)
Precio objetivo analistas
106,99 USD (puede no estar actualizado)
Primera cotización
25/06/2015
Precio actualizado
hace 12 horas
Sobre la empresa

Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in diagnosis and treatment of heart, cancer, and other diseases worldwide. The company offers DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. It also provides Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; PYLARIFY AI, an medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer; and flurpiridaz used to assess blood flow to the heart. In addition, it develops PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy to patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent for Tau tangles in Alzheimer's disease; LNTH-2401, a novel radiodiagnostic targeting the gastrin-releasing peptide receptor; LNTH-2402; LNTH-2403; LNTH-2404; LNTH-250; LNTH-2515; and LNTH-1363S, an fibroblast activation protein, alpha, copper-64 labeled PET imaging agent. It has collaboration agreements with GE Healthcare; Curium Pharma; POINT; Regeneron; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts.

Rentabilidad mensual
Evolución
Histórico día a día
Fecha Apertura Máximo Mínimo Cierre Variación Volatilidad día Volumen
15/04/2025 102,30 104,00 100,48 102,78 +0,64% 3,44% 602.600
14/04/2025 102,61 103,00 99,53 102,13 +0,13% 3,38% 703.900
11/04/2025 98,51 102,27 96,00 102,00 +3,54% 6,36% 732.100
10/04/2025 97,65 99,59 93,88 98,51 -1,65% 5,85% 1.153.500
09/04/2025 91,65 101,35 91,65 100,16 +7,23% 10,58% 958.700
08/04/2025 96,54 98,71 92,14 93,41 -2,14% 6,81% 1.163.200
07/04/2025 85,90 96,27 85,00 95,45 +4,98% 13,11% 1.802.700
04/04/2025 92,49 93,86 89,12 90,92 -6,47% 5,12% 1.158.300
03/04/2025 95,10 98,70 93,67 97,21 -0,22% 5,29% 764.700
02/04/2025 96,66 98,42 95,18 97,42 -0,52% 3,35% 550.700
01/04/2025 97,61 98,64 94,69 97,93 +0,34% 4,04% 675.400
31/03/2025 94,98 98,98 93,61 97,60 +1,50% 5,65% 1.077.600
28/03/2025 96,66 97,39 94,75 96,16 -0,91% 2,73% 617.700
27/03/2025 99,09 100,06 97,00 97,04 -1,41% 3,09% 681.800
26/03/2025 99,56 100,73 97,06 98,43 -1,34% 3,69% 526.000
25/03/2025 99,36 100,45 97,32 99,77 +0,33% 3,15% 529.500
24/03/2025 98,99 100,20 97,50 99,44 +1,77% 2,73% 646.400
21/03/2025 97,61 99,05 94,80 97,71 -1,15% 4,35% 1.069.500
20/03/2025 101,47 103,99 97,49 98,85 -4,29% 6,41% 655.200
19/03/2025 101,80 103,59 101,35 103,28 +1,04% 2,20% 505.700
18/03/2025 102,00 103,86 100,28 102,22 -0,53% 3,51% 530.100
17/03/2025 100,52 102,94 100,24 102,76 +1,64% 2,69% 492.200
14/03/2025 99,43 101,28 99,30 101,10 +1,82% 1,99% 454.600
13/03/2025 100,19 103,53 99,10 99,29 -1,55% 4,42% 724.100
12/03/2025 105,13 105,67 97,77 100,85 -3,60% 7,51% 1.256.300
11/03/2025 110,22 111,29 104,42 104,62 -4,90% 6,23% 1.345.500
10/03/2025 105,65 111,29 104,54 110,01 +3,45% 6,39% 1.608.100
07/03/2025 100,24 107,26 99,78 106,34 +6,10% 7,46% 1.370.600
06/03/2025 99,79 102,26 98,67 100,23 -0,25% 3,60% 878.600
05/03/2025 98,00 101,33 96,22 100,48 +2,35% 5,21% 1.108.300